AbbVie Inc.
AbbVie is a global biopharmaceutical company that researches, develops, manufactures, markets and sells medicines and therapies for serious diseases. It operates as a single global business segment, with commercial activities organized by geographic region or therapeutic area. Its products address areas including immunology, neuroscience, oncology, aesthetics and eye care, as well as conditions such as hepatitis C and digestive disorders. Brands include Skyrizi, Rinvoq, Humira, Vraylar, Botox Therapeutic, Imbruvica, Venclexta, Botox Cosmetic and Juvederm Collection. AbbVie makes money by selling its products worldwide through dedicated and regional commercial teams, distributors and wholesalers, as well as directly to some health care providers and other customers. It directs marketing efforts to physicians and other health care providers, payers, hospitals and government agencies, and also markets directly to consumers. AbbVie is headquartered in North Chicago, Illinois.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ABBV in the last 30 days.
See all $ABBV insider activity →AbbVie (ABBV) reported Q3 earnings, maintaining oncology revenue guidance of $6.6b for 2026, with Venclexta and Imbruvica contributing $3.1b and $2.1b respectively. The company is advancing new treatments, offsetting concerns about Imbruvica's performance. Analysts highlight potential undervaluation in three unspecified companies.
Raleigh-Durham's economy is diversifying beyond life sciences, attracting investments in tech, semiconductors, and advanced manufacturing. The region saw $4.4B in life sciences VC funding (2019-2024) and now has $140B in manufacturing investments. Companies like AbbVie ($1.4B) and Caterpillar ($1B) are expanding operations, driven by demand and workforce strengths.
AbbVie will pay $100M upfront (up to $1.47B total) to license NXE0033744, an IBD drug from Nxera Pharma. The drug targets gut cell death, unlike AbbVie's Skyrizi and Rinvoq, which focus on immune responses. NXE0033744 is designed to be gut-restricted, avoiding systemic side effects. The deal is subject to antitrust clearance.
Over the past 7 days, AlphAI's AI scored 103 news stories mentioning ABBV (AbbVie Inc.). Coverage has skewed bullish: 87 bullish, 12 neutral, and 4 bearish.
Recent ABBV coverage spans financial news, mergers & acquisitions and earnings.
Guidance suggests strong oncology revenue, likely supporting the stock.
The sizable capex signals long‑term growth in AbbVie's manufacturing footprint.
The licensing agreement adds a novel gut‑restricted IBD asset to AbbVie's pipeline, potentially boosting future revenue.
Analyst upgrade and higher price target suggest upside potential.
The deal adds a promising IBD asset to AbbVie's pipeline, potentially boosting its long‑term growth outlook.
AlphAI scores every news story that mentions ABBV with an AI model for sentiment and relevance, and aggregates insider trades from AbbVie Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
AbbVie (ABBV) reported Q3 earnings, maintaining oncology revenue guidance of $6.6b for 2026, with Venclexta and Imbruvica contributing $3.1b and $2.1b respectively. The company is advancing new treatments, offsetting concerns about Imbruvica's performance. Analysts highlight potential undervaluation in three unspecified companies.
Raleigh-Durham's economy is diversifying beyond life sciences, attracting investments in tech, semiconductors, and advanced manufacturing. The region saw $4.4B in life sciences VC funding (2019-2024) and now has $140B in manufacturing investments. Companies like AbbVie ($1.4B) and Caterpillar ($1B) are expanding operations, driven by demand and workforce strengths.
AbbVie will pay $100M upfront (up to $1.47B total) to license NXE0033744, an IBD drug from Nxera Pharma. The drug targets gut cell death, unlike AbbVie's Skyrizi and Rinvoq, which focus on immune responses. NXE0033744 is designed to be gut-restricted, avoiding systemic side effects. The deal is subject to antitrust clearance.
Freedom Broker raised its price target on AbbVie (NYSE:ABBV) to $315 from $285, citing strong quarterly results and raised guidance. The company's revenue grew 10.68% over the last twelve months, with shares trading near their 52-week high. Several other analysts also increased their price targets following AbbVie's strong third-quarter performance, which exceeded estimates.
Boehringer Ingelheim licensed six oncology programs from Sino Biopharmaceutical for $358M upfront, with $7B in potential milestones. Nxera Pharma licensed an EP4 agonist to AbbVie for $100M upfront, with $1.37B in potential milestones. Both deals highlight pharma's reliance on external innovation.
Exxon Mobil (XOM) raised its dividend for the 44th year, increasing it by 4% to $1.07 per share. Chevron (CVX), AbbVie (ABBV), and ONEOK (OKE) also raised their dividends. All four companies reported strong free cash flow and analyst support. Exxon's dividend yield is 2.35%, Chevron's is 2.87%, AbbVie's is 2.28%, and ONEOK's is 4.46%.
AbbVie is expanding its R&D facility in Oxford, UK, with a £120m investment. Separately, it signed a $1.38bn deal with Nxera for an IBD drug. The company aims to strengthen its immunology portfolio and benefit from the UK's life sciences growth.
AbbVie (ABBV) filed its quarterly report (10-Q) with the SEC on November 3, 2026. The report includes financial statements and exhibits. Investors can review the filing for updates on the company's performance and financial health.
AbbVie (ABBV) won a court ruling that exempts Botox from Medicare's drug price negotiation program, as a key ingredient is derived from human plasma. U.S. District Judge Carl J. Nichols ruled that CMS incorrectly interpreted the exemption. The case began after CMS selected Botox for 2028 pricing negotiations. The decision may impact Medicare pricing and future drug selections.
AbbVie has expanded its Oxford R&D facility as part of a £120M+ investment, focusing on immunology, neuroscience, and oncology. The expansion follows the 2022 acquisition of DJS Antibodies and aims to identify new disease targets and therapies. AbbVie collaborates with over 100 UK universities, including the University of Oxford.
